Hers, Hims and food and drug administration

Hims & Hers warns it may stop selling compounded weight-loss drugs
Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo Nordisk because its pathway to do so closed when the U.S. FDA declared Friday that the drug's shortage was over.
Hims & Hers shares tumble after company misses on margin, says may stop selling some weight loss drugs
Hims & Hers Health reported fourth-quarter results on Monday that beat analysts' expectations, but the stock sank in extended trading.
A new generation of weight-loss drugs move beyond GLP-1
Glucagon-like peptite-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With the potential to significantly change consumer eating habits, they are forcing the industry to think about nutrient-dense foods catering for those with smaller appetites.
These Drugs Could Offset the Side Effects of Weight Loss
Popular weight-loss therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss.
Hims & Hers Shares Plunge as Costs Tied to Weight-Loss Drugs Squeeze Margins
Shares of Hims & Hers Health (HIMS) shares plunged in late trading Monday after the company reported falling margins as costs rose, overshadowing better-than-expected sales. The online healthcare provider’s fourth-quarter revenue nearly doubled year-over-year to $481.

FDA, Novo Nordisk and Wegovy and Ozempic

Wall Street Thinks This Weight Loss Drug Stock Could More Than 3X Over the Next 12 Months -- and It's Not Eli Lilly or Novo Nordisk
Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as ...
Shortage of Novo Nordisk’s (NVO) Weight Loss Drugs Is Resolved, Says FDA
The shortage of Novo Nordisk’s (NVO) blockbuster weight loss drugs has been resolved, according to the U.S. Food and Drug ...
Yearslong shortage of popular weight-loss and diabetes drugs resolved, FDA says
Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...
FiercePharma3d
Novo Nordisk's semaglutide shortage officially concludes in the US, spelling major threat for weight loss drug compounders
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
Why Novo Nordisk Stock Popped on Friday
Novo Nordisk ( NVO 5.29%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly ...
Weight-loss drugs are about to get a lot better
A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.
Are Weight Loss Injections Safe? What to Know Before Starting One
Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...